Weight Loss & Metabolic / side effects and safety / Last reviewed 2026-06-02

AOD-9604 Side Effects: Safety Signals and Warnings

AOD-9604 safety concerns are compound-specific. The main listed side effects are Injection site irritation, Headache, and Mild nausea. The main warning signals are Not FDA approved for any indication, Human clinical trials for obesity did not meet primary endpoints, and Quality and purity of research-grade peptides may vary significantly.

Read the full AOD-9604 guide Browse answer pages

Direct Answer

Evidence for AOD-9604 is too preliminary to support a research protocol with confidence. The compound's Phase 3 trial failed on the primary endpoint, returning negative efficacy data for weight loss in humans. Of the Weight Loss & Metabolic compounds in this library, semaglutide, tirzepatide, or retatrutide have vastly stronger evidence bases as starting points.

Evidence grade
Level D
Research status
Preclinical
Category
Weight Loss & Metabolic
Best for
No validated human application - mechanistic lipolysis research only

Reported Side Effects

Warnings

Known or Plausible Interactions

Regulatory Context

Not FDA approved. Available as a research chemical in some jurisdictions. GRAS status granted by FDA for use in food supplements in specific contexts. Banned by WADA.

Evidence Snapshot

Evidence gradeLevel D
Research statusPreclinical
Best supported outcomesFat Mass Reduction (Level D) and Cartilage Repair (Level D)
Primary citation count2
Last reviewed2026-06-02

Related Guides

How to Cite This Page

ExaminePeptides. "AOD-9604 Side Effects: Safety Signals and Warnings." Last reviewed 2026-06-02. https://examinepeptides.com/answers/aod-9604-side-effects-safety/

This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.